Welcome : Guest

Celyad S.A. (Belgium) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Celyad S.A., which is principally involved in Drug Developing Business. Illustrated with 62 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-65982
Price: $3100
Company Type: Public
Pages: 65
Date: March 2017
Market Data Tables: 62

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Cardio Vascular Diseases (CVD)......4
Table 1: Cardiac & Vascular Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for Americas, Asia and Others, Europe, and Japan......4
Table 2: Cardio Vascular Diseases (CVD) Market by Cause of Death in the US (2015) - Percentage Share Breakdown by Volume for Coronary Heart Disease, Diseases of the Arteries, Heart Failure, High Blood Pressure, Stroke, and Others......5
Table 3: Cardiovascular Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for ACE Inhibitors, Alpha Blockers, Angiotensin Receptor Blockers, Anti-Arrhythmics, Anti-Thrombotics, Beta Blockers, Calcium Channel Blockers, Cholesterol, GP IIb/IIIa Inhibitors, Vasodilators, and Others......6
Immunotherapy......7
Table 4: Immunotherapy Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union, United States and Rest of the World......7
Table 5: Immunotherapy Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Subcutaneous, and Sublingual......8
Table 6: No. of Patients for Immunotherapy by Age Group in the US (2015) - Percentage Market Share Breakdown by Value for 0-4 Patient Pool, 10 - 14 Patient Pool, 15 - 19 Patient Pool, 5-9 Patient Pool, Adult Patient Pool (over 65), and Adult Patient Pool (under 65)......9
Table 7: No. of Patients for Immunotherapy by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Europe, North America, and Others......10
Peripheral Vascular......11
Table 8: Peripheral Vascular Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Amputation, Atherectomy, Bypass, Percutaneous Transluminal Angioplasty (PTA) Stents, and Others......11
Table 9: Peripheral Vascular Procedures Market by Segment in the US (2015) - Percentage Share Breakdown by Volume for Aorto Femoral, Endovascular Aneurysm Repair (EVAR) and Endoleak, Upper Extremity and Thorack, Visceral, Uterine Fibroid Embolization, Endovascular Aneurysm Repair (fEVAR) and Thoracic Endovascular Aortic Repair (fTEVAR)......12
Table 10: Vascular Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Diagnostic (Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)), Percutaneous Coronary Intervention (PCI), Peripheral Interventions, and Structural Vascular......13
Table 11: Vascular Market by Product Segment Worldwide (2015) - Percentage Breakdown by Value for Biopsy, Electrophysiology, Grafts, PTA Catheters, Self-Expanding Stents & Stent Grafts, and Vena Cava Filters......14
Table 12: Vascular Access Market by Product Worldwide (2015) - Percentage Share Breakdown by Value for Arterial, Central Venous Catheter (CVC), Peripherally Inserted Central Catheter (PICC), and Vascular Positioning System (VPS)......15
Cancer Drugs......16
Table 13: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......16
Table 14: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......17
Cancer Market......18
Table 15: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others*......18
Table 16: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......19
Table 17: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......20
Table 18: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......21
Table 19: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......22
Table 20: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......23
Table 21: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......24
Table 22: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......25
Cancer Patients......26
Table 23: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......26
Table 24: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......27
Table 25: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......28
Table 26: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......29
Table 27: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......30
Table 28: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......31
Table 29: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......32
Table 30: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......33
Table 31: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......34
Table 32: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......35
Table 33: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......36
Table 34: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......37
Table 35: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......38
Table 36: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......39
Table 37: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......40
Table 38: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......41
Table 39: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......42
Table 40: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......43
Table 41: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......44
Table 42: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......45
Table 43: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......46
Cervical Cancer......47
Table 44: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......47
Table 45: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......48
Hematological Cancer......49
Table 46: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......49
Skin Cancer......50
Table 47: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......50
Cancer-Associated Mucositis......51
Table 48: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......51
Chronic Myelogenous Leukemia (CML)......52
Table 49: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......52
Multiple Myeloma......53
Table 50: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......53
Table 51: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......54
Cancer Drugs......55
Table 52: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......55
Table 53: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......56
Table 54: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......57
Table 55: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......58
Table 56: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......59
Breast Cancer Drugs......60
Table 57: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......60
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......61
Table 58: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......61
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......62
Table 59: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......62
Table 60: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......63
Cardio-Cerebral Vascular (CCV) Drugs......64
Table 61: Market Shares of Leading Cardio-Cerebral Vascular (CCV) Drugs Manufacturers in China (2015) - Percentage Share Breakdown by Value for Sihuan Pharmaceutical Holdings Group Ltd., Sanofi S.A., Qilu pharmaceutical Co., Ltd. and Others......64
Vascular......65
Table 62: Market Shares of Leading Vascular Equipment Manufacturers Worldwide (2015) - Percentage Breakdown by Value for AngioDynamics, Inc., C. R. Bard, Inc., Navillst, Teleflex, Inc., and Others......65